MSD Receives Positive CHMP Opinion For Pembrolizumab For The Treatment Of Advanced Melanoma

MSD, known as Merck (NYSE:MRK) in the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of pembrolizumab.

Link:
www.businesswire.com/news/home/20150522005288/en/MSD-Receives-Positive-CHMP-Opinion-Pembrolizumab-Treatment#.VV8UVaW1Gko